Bae et al. delineated in their study that ACY241, an HDAC6 inhibitor, up-regulated anti-tumor activity of antigen-specific cytotoxic T lymphocyte against MM cells by increasing CD107a, IFN-γ, TNF-α and IL2 production [38]. This evidence concerns the gene HDAC6 and Miyoshi myopathy.